Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
LLC cells
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "LLC cells" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-U00433A
CAS No.: 2448414-54-6
Target:
Research Areas:
JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells.
1
Category:
Flavonols Flavonoids Monophenols Phenols Plants Other Families Extract Disease Research Fields Inflammation/Immunology
Target:
1
Cat. No.: HY-162275
CAS No.: 861224-48-8
Research Areas:
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
Cat. No.: HY-161574
CAS No.: 3061315-33-8
Target:
Research Areas:
LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC50 of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) .
Cat. No.: HY-162540
Target:
Research Areas:
LLC355 is a discoidin domain receptor 1 (DDR1) ATTEC degrader with a DC50 of 150.8 nM. LLC355 induces DDR1 protein degradation via lysosome-mediated autophagy. LLC355 inhibits the tumorigenicity, migration and invasion abilities of cancer cells, and induces apoptosis. LLC355 is applicable to research related to non-small cell lung cancer and pancreatic cancer .
Cat. No.: HY-125664
CAS No.: 480439-84-7
Target:
Cat. No.: HY-169122
Target:
Research Areas:
LLC1 is an Amiloride (HY-B0285) derivative with cytotoxicity against breast cancer cells, particularly those resistant to treatment. The IC50 values of LLC1 for MCF7, MCF7 MX-100, MCF7 TS, MCF7 TR-1, and MCF7 TR-5 are 13, 12, 25, 26, and 19 mM, respectively. LLC1 shows potential for research in the field of cancer therapy .
Cat. No.: HY-122379
CAS No.: 81426-17-7
Target:
Cat. No.: HY-122783
CAS No.: 149655-52-7
Target:
Cat. No.: HY-172951
Antitrypanosomal agent 23 is an antitrypanosomal agent. Antitrypanosomal agent 23 has activity against intracellular amastigotes of T. cruzi in LLC-MK2 and C2C12 cells (IC50: 0.10 and 0.11 μM). Antitrypanosomal agent 23 is a weak inhibitor of Recombinant trans-sialidase from T. cruzi (TcTS) (IC50: 1.1 mM) .
Cat. No.: HY-175182
Research Areas:
IDO1-IN-27 (Compound I-1) is a Indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitor with an IC50 of 0.3951 μM for recombinant hIDO1. IDO1-IN-27 also inhibits hIDO1 expression in HeLa cells (EC50: 62 nM). IDO1-IN-27 effectively stimulates T cell proliferation by reducing the mRNA expression of pro-inflammatory factors (TNF-α, IL-6, and IL-1β) while concurrently inhibiting LLC cells growth .
Category:
Alkaloids Piperidine Alkaloids Microorganisms Pyrrole Alkaloids Solanum tuberosum Linn. Plants Disease Research Fields Cancer Solanaceae Extract
Target:
Cat. No.: HY-185557
CAS No.: 3063448-59-6
Target:
Research Areas:
LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia .
Cat. No.: HY-D3200
CAS No.: 3112200-59-3
Target:
Research Areas:
Dns-LLC is a cell-permeable Cu +-selective fluorescent probe that forms a 1:1 complex with Cu +. The thiol group of Dns-LLC plays a key binding role, while the sulfonamide and amide groups jointly contribute to the stabilization of the complex. Upon binding to Cu + in aqueous buffer solutions, Dns-LLC generates a turn-on fluorescence response, which can be used for the detection of Cu + in the Golgi apparatus .
Cat. No.: HY-W1005059
CAS No.: 42472-93-5
Target:
Research Areas:
N-Methylthalidomide is a cereblon ligand derivative that acts as an E3 ubiquitin ligase ligand for the synthesis of PROTAC LLC0424N (HY-185557). LLC0424N serves as a negative control for NSD2 PROTAC degrader LLC0424 (HY-161574), with weak ability to induce NSD2 degradation and low growth inhibitory effect on cancer cells carrying NSD2 mutations .
Cat. No.: HY-P11934
Target:
Research Areas:
Cat. No.: HY-184918
CAS No.: 3097045-01-4
Target:
Research Areas:
NAMPT/PD-1/PD-L1-IN-1 is a potent the PD-1/PD-L1 interaction and NAMPT dual inhibitor with IC50s of 7.5 nM and 18.8 nM, respectively. NAMPT/PD-1/PD-L1-IN-1 enhances T cell-mediated tumor cell killing, promotes T cell proliferation and CD8 + T cell proportion and depletes intracellular NAD + biosynthesis. NAMPT/PD-1/PD-L1-IN-1 suppresses tumor progression in a mouse LLC xenograft model by disrupting tumor metabolism and activating the tumor immune microenvironment. NAMPT/PD-1/PD-L1-IN-1 can be used in research on tumor immunotherapy for non-small cell lung cancer .
Cat. No.: HY-181663
Target:
Research Areas:
PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC50 of 414 nM against PD-1/PD-L1, an IC50 of 786 nM against JAK1, a Ka of 294 nM for human PD-1/PD-L1, and a Ka of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3 +CD8 + and CD3 +CD4 + cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
